A comprehensive comparative analysis published in Discover Public Health demonstrates that emerging hantavirus outbreaks and the global Coronavirus Disease 2019 pandemic share critical molecular, clinical, and immunopathological hallmarks despite exhibiting fundamentally divergent transmission dynamics and case fatality trajectories. Conducted by researchers Salma Madihi, Warda Baha, and Abdelouaheb Benani, the systematic investigation synthesizes evidence from major biomedical databases including PubMed and Google Scholar, alongside technical evaluations from the World Health Organization and the Centers for Disease Control and Prevention. The review establishes that while both pathogens initiate profound systemic disease driven by microvascular damage and excessive immune activation, their public health footprints diverge significantly due to contrasting environmental reservoirs and modes of contagion. Zoonotic infections account for an estimated 2.7 million human deaths annually, highlighting an urgent need to translate the hard-won operational, diagnostic, and surveillance lessons acquired during the pandemic response into proactive countermeasures against neglected zoonoses that maintain persistent reservoirs in wildlife populations.
The critical impetus for examining public health readiness arose following a maritime outbreak of Andes virus aboard the expedition cruise vessel MV Hondius, which departed Ushuaia, Argentina, on April 1, 2026, carrying 147 passengers and crew members across a South Atlantic itinerary. By May 4, 2026, health authorities had identified seven related cases, including two laboratory-confirmed infections, five suspected cases, and three early fatalities, presenting severe respiratory distress that required international coordination after Cabo Verde denied the ship docking permissions. Disembarkation was subsequently coordinated by the World Health Organization and Spanish authorities on the island of Tenerife in the Canary Islands, illustrating the intricate legal and jurisdictional barriers governing maritime quarantine protocols. By July 2, 2026, the cluster had expanded to thirteen total cases comprising twelve laboratory-confirmed infections and one probable case across Dutch, British, Spanish, German, Swiss, French, and Canadian nationals. Yielding an alarming case fatality rate of 23 percent, the incident demonstrated how modern international travel circuits can rapidly distribute rare pathogens carrying extended incubation periods across multijurisdictional boundaries.
Virological comparisons reveal structural and genetic contrasts that govern how these enveloped RNA viruses interact with human hosts and adapt across ecological niches. Severe Acute Respiratory Syndrome Coronavirus 2 is classified within the family Coronaviridae and order Nidovirales as a single-stranded, positive-sense RNA virus possessing a genome that encodes four major structural proteins: envelope, membrane, nucleocapsid, and the surface spike glycoprotein. Host entry requires the spike protein to bind cellular angiotensin-converting enzyme 2 receptors before cleavage by host proteases, specifically TMPRSS2 and ADAM17, to facilitate cellular membrane fusion. In contrast, hantaviruses belong to the family Hantaviridae within the order Bunyavirales, maintaining a negative-sense, single-stranded RNA genome divided into three distinct segments: small, medium, and large. These viral segments encode the structural nucleoprotein, the surface envelope glycoproteins Gn and Gc, and the viral RNA-dependent RNA polymerase. While coronaviruses evolve through rapid point mutations and frequent genetic recombination, hantaviruses maintain evolutionary diversity through genetic mutation, reassortment, and long-term co-divergence with specific small mammal reservoirs.
Contrasting transmission biology heavily dictates the distinct public health containment strategies required for each infectious agent. Severe Acute Respiratory Syndrome Coronavirus 2 transmits efficiently between human hosts through respiratory droplets and microscopic aerosols expelled during breathing, speaking, singing, coughing, or sneezing, resulting in widespread airborne spread within crowded or poorly ventilated indoor spaces. Its brief incubation window, typically lasting between two and seven days, facilitated exponential community transmission that produced over 704 million confirmed cases and more than seven million deaths worldwide by April 2024. Conversely, hantaviruses are predominantly contracted through the inhalation of aerosolized excreta, saliva, or dust contaminated by infected rodents, generally lacking the capacity for sustained human-to-human transmission. Andes virus represents the notable exception, possessing documented capacity for secondary human transmission during intimate, prolonged contact within households or early prodromal periods, as observed during historical outbreaks in Argentina and Chile. Compounding contact tracing challenges, hantavirus incubation periods range from one to six weeks, with Andes virus displaying an incubation span of 7 to 39 days and a median of 18 days.
At the cellular level, the investigation highlights that severe illness in both viral syndromes is anchored in extensive endothelial injury and dysregulated inflammatory cascades rather than unconstrained direct cellular cytopathicity. Pathogenic hantaviruses utilize surface glycoproteins Gn and Gc to attach to beta-integrin receptors on human endothelial cells without necessarily destroying the infected cellular architecture, yet their presence disrupts endothelial barrier integrity to induce profound vascular hyperpermeability. Severe Acute Respiratory Syndrome Coronavirus 2 produces comparable systemic microvascular damage, triggering glycocalyx shedding, coagulation abnormalities, and unrestrained cytokine release characterized by elevated interleukin-6, interferon-gamma, interferon-gamma-inducible protein-10, and monocyte chemoattractant protein-1. Bioinformatic evaluations identified 32 shared genes between Coronavirus Disease 2019 and hemorrhagic fever with renal syndrome, highlighting six central regulatory hub genes: RAD51, ALDH1A1, UBA52, CUL3, GADD45B, and CDKN1A. Concomitant clinical studies indicate that patients suffering from hemorrhagic fever with renal syndrome who experience concurrent coronavirus infection face compounded clinical risks, demonstrating lengthened hospitalizations, more pronounced organ damage, and elevated overall mortality rates compared to patients experiencing monoinfection.
Geographic and clinical expressions across global populations reflect the ecological diversity of their underlying animal reservoirs. Coronaviruses maintain broad natural reservoirs among bats, with ongoing investigations examining potential intermediate hosts, while demonstrating capacity for reverse zoonotic transmission into captive tigers, lions, hyenas, farmed mink, and wild deer. Hantaviruses, by contrast, exhibit tight evolutionary specialization alongside specific rodent hosts, dividing epidemiologically into Old World and New World lineages that generate between 10,000 and 100,000 human infections annually. Old World species, such as Hantaan virus carried by the striped field mouse Apodemus agrarius and Puumala virus hosted by the bank vole Myodes glareolus, cause hemorrhagic fever with renal syndrome across Europe and Asia with case fatality rates ranging from under 1 percent to 15 percent. New World strains cause hantavirus cardiopulmonary syndrome across the Americas, where Sin Nombre virus, Bayou virus carried by the marsh rice rat Oryzomys palustris, Maripa virus, and Andes virus hosted by Oligoryzomys longicaudatus generate severe cardiopulmonary failure and shock, producing mortality rates reaching up to 50 percent.
Diagnostic workflows illustrate another critical operational vulnerability where hantavirus management lags far behind the massive testing infrastructure deployed during the coronavirus pandemic. Coronavirus diagnostic services rely upon real-time reverse transcription polymerase chain reaction assays as a gold standard within Biosafety Level 2 containment, supported by loop-mediated isothermal amplification platforms and widely distributed rapid antigen lateral flow immunoassays using nasopharyngeal swabs. Laboratory verification of hantavirus infection, however, remains predominantly dependent upon serological detection of specific immunoglobulin M antibodies or documented rises in immunoglobulin G titers, because acute-phase viremia is frequently fleeting. When molecular testing is conducted for Andes virus, whole blood or buffy coat specimens serve as optimal sample matrices due to distinct viral tropism for circulating mononuclear cells. Routine patient testing requires Biosafety Level 2 facilities, whereas viral culture, propagation, and handling of infectious animal tissues mandate strict Biosafety Level 3 precautions. Managing the MV Hondius cluster required the World Health Organization to coordinate rapid shipment of diagnostic kits from Argentina to five countries, with testing conducted at specialized reference facilities in South Africa and Senegal.
The comparative review delineates sharp disparities regarding clinical therapeutics and licensed countermeasure pipelines across both diseases. The pandemic response stimulated rapid repurposing and clinical licensing of small-molecule antivirals, including remdesivir, molnupiravir, and nirmatrelvir boosted with ritonavir, alongside convalescent plasma and recombinant monoclonal antibodies targeting the viral spike protein. In contrast, no antiviral agents have received Food and Drug Administration approval specifically indicated for hantavirus infections, leaving clinical management almost entirely supportive. Patients suffering from severe hemorrhagic fever with renal syndrome require precise fluid and electrolyte monitoring combined with renal replacement therapy or dialysis, whereas severe hantavirus cardiopulmonary syndrome demands intensive mechanical ventilation and early extracorporeal membrane oxygenation rescue. The broad-spectrum nucleoside analogue ribavirin demonstrates in vitro and Syrian hamster model efficacy against Andes virus and offers partial clinical benefits in renal syndrome, yet human trials show no therapeutic benefit in cardiopulmonary disease. Preclinical investigations evaluating favipiravir and neutralizing monoclonal antibodies targeting Gn and Gc glycoproteins, including JL16 and SAB-163, show experimental promise but face structural instability hurdles during recombinant protein production.
Disparities in preventative immunization further accentuate global vulnerability to emerging rodent-borne pathogens. The coronavirus pandemic catalyzed the development and global administration of over 13.6 billion vaccine doses by December 2023, utilizing mRNA-lipid nanoparticle formulations, adenoviral vectors, protein subunits, and inactivated platforms to achieve complete primary series coverage across approximately 67 percent of the human population. Conversely, no globally standardized or widely authorized vaccine exists for hantavirus prevention. Formalin-inactivated vaccines derived from suckling mouse brain tissue, notably Hantavax targeting Hantaan and Seoul viruses, have been deployed in South Korea and China since the late 1980s, achieving 97 percent seroconversion one month after booster administration; however, neutralizing antibody titers decline to approximately 50 percent after one year without demonstrating statistically significant reductions in clinical disease severity. Advanced preclinical research is currently evaluating next-generation nucleic acid platforms, including mRNA-lipid nanoparticles encoding Andes virus glycoproteins and virus-like particles displaying intact Gn and Gc proteins, which have induced complete protection and high neutralizing antibody responses in rodent challenge models, demonstrating that modern platform technologies can be adapted for neglected viral threats.
Mitigating future zoonotic spillovers requires transitioning from reactive outbreak containment to predictive epidemic intelligence embedded within a comprehensive One Health framework. Environmental disturbances, including deforestation, agricultural expansion, and climate anomalies like historic El Niño events in the southwestern United States, repeatedly drive dramatic fluctuations in rodent reservoir densities that precede human infection spikes. Ecological restoration provides a direct public health defense; for example, reforesting Brazil’s Atlantic Forest to statutory mandates could reduce hantavirus spillover risk by approximately 45 percent by reducing densities of generalist reservoir species such as Oligoryzomys nigripes and Necromys lasiurus. Concurrently, epidemic surveillance must incorporate artificial intelligence architectures, such as the proposed Hantavirus Risk Prediction Artificial Intelligence framework, which merges syndromic tracking, climate metrics, rodent population surveys, and cross-border mobility data to identify subtle pre-outbreak signals. Coupled with international genomic monitoring networks pioneered during the pandemic, proactive One Health coordination offers the essential architecture to detect, characterize, and contain virulent zoonotic pathogens before localized transmissions expand across vulnerable global populations.
Subject of Research: Comparative epidemiology, virology, and public health preparedness for COVID-19 and hantavirus infections
Article Title: Learning from COVID-19 to strengthen hantavirus preparedness and public health response
Article References: Madihi, S., Baha, W., & Benani, A. (2026). Learning from COVID-19 to strengthen hantavirus preparedness and public health response. Discover Public Health, 23(1), Article 1799. https://doi.org/10.1186/s12982-026-03193-2
Image Credits: AI Generated
DOI: 10.1186/s12982-026-03193-2
Keywords: hantavirus, COVID-19, Andes virus, SARS-CoV-2, zoonotic spillover, endothelial dysfunction, One Health, hantavirus cardiopulmonary syndrome, hemorrhagic fever with renal syndrome, epidemic intelligence, MV Hondius outbreak, biosafety containment, monoclonal antibodies, genomic surveillance, rodent reservoirs, Hantavax, vaccine development, viral pathogenesis